Nuwellis, Inc. NUWE

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
44/100
Developing

About Nuwellis, Inc.

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals … Full NUWE analysis →

Competitive advantage assessment

Key strengths

  • Comfortable Interest Coverage Interest coverage quality is strong vs peers (score 0.71). Debt servicing capacity supports continued M&A optionality.
  • Improving FCF Trend FCF trend score is positive (score 0.81). Improving FCF margin signals compounding operational leverage.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.06). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.30). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
52

Where NUWE ranks in Medical Devices

Nuwellis, Inc. ranks #94 of 160 scored companies in Medical Devices by moat score — the top 59%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

Moat scores for companies ranked near NUWE in Medical Devices
# Company Moat score Rating
90 Pheton Holdings Ltd PTHL 45/100 Developing
91 IRIDEX Corporation IRIX 45/100 Developing
92 Catheter Precision, Inc. VTAK 44/100 Developing
93 MaxCyte, Inc. MXCT 44/100 Developing
94 Nuwellis, Inc. NUWE 44/100 Developing
95 Helius Medical Technologies, In HSDT 44/100 Developing
96 Trinity Biotech plc TRIB 44/100 Developing
97 Nexalin Technology, Inc. NXLIW 44/100 Developing
98 Outset Medical, Inc. OM 44/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How NUWE scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 52 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 11 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 53 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 52 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 66 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 30 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding NUWE's moat

What is Nuwellis, Inc.'s moat score?

Nuwellis, Inc. (NUWE) scores 44 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #94 of 160 scored companies in Medical Devices, the top 59%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Capital Structure & Resilience (66/100) and its weakest is R&D Pipeline & Capital Returns (11/100).

How does Nuwellis, Inc. compare with other Medical Devices companies?

Nuwellis, Inc. ranks #94 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are MaxCyte, Inc. (MXCT) at 44 just above it and Helius Medical Technologies, In (HSDT) at 44 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Nuwellis, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Nuwellis, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and NUWE scores: Pricing Power & Consumable Moat (52), R&D Pipeline & Capital Returns (11), FCF Quality & Cash Conversion (53), Commercial Execution (52), Capital Structure & Resilience (66), Growth Durability (30). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000